Literature DB >> 25446019

Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations.

Marie-Lucile Figueres1, Agnès Linglart2, Frank Bienaime3, Emma Allain-Launay4, Gwenaelle Roussey-Kessler5, Amélie Ryckewaert6, Marie-Laure Kottler7, Maryvonne Hourmant8.   

Abstract

Loss-of-function mutations of CYP24A1, the enzyme that converts the major circulating and active forms of vitamin D to inactive metabolites, recently have been implicated in idiopathic infantile hypercalcemia. Patients with biallelic mutations in CYP24A1 present with severe hypercalcemia and nephrocalcinosis in infancy or hypercalciuria, kidney stones, and nephrocalcinosis in adulthood. We describe a cohort of 7 patients (2 adults, 5 children) presenting with severe hypercalcemia who had homozygous or compound heterozygous mutations in CYP24A1. Acute episodes of hypercalcemia in infancy were the first symptom in 6 of 7 patients; in all patients, symptoms included nephrocalcinosis, hypercalciuria, low parathyroid hormone (PTH) levels, and higher than expected 1,25-dihydroxyvitamin D levels. Longitudinal data suggested that in most patients, periods of increased sunlight exposure tended to correlate with decreases in PTH levels and increases in calcemia and calciuria. Follow-up of the 2 adult patients showed reduced glomerular filtration rate and extrarenal manifestations, including calcic corneal deposits and osteoporosis. Cases of severe PTH-independent hypercalcemia associated with hypercalciuria in infants should prompt genetic analysis of CYP24A1. These patients should be monitored carefully throughout life because they may be at increased risk for developing chronic kidney disease.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  1,25-dihydroxyvitamin D (1,25[OH](2)D); 24α-hydroxylase; CYP24A1; chronic kidney disease (CKD); hypercalcemia; hypercalciuria; hypervitaminosis D; idiopathic infantile hypercalcemia (IIH); nephrocalcinosis; parathyroid hormone (PTH); vitamin D metabolism

Mesh:

Substances:

Year:  2014        PMID: 25446019     DOI: 10.1053/j.ajkd.2014.06.037

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  18 in total

1.  A novel CYP24A1 genotype associated to a clinical picture of hypercalcemia, nephrolithiasis and low bone mass.

Authors:  Pietro Manuel Ferraro; Angelo Minucci; Aniello Primiano; Elisa De Paolis; Jacopo Gervasoni; Silvia Persichilli; Alessandro Naticchia; Ettore Capoluongo; Giovanni Gambaro
Journal:  Urolithiasis       Date:  2016-09-17       Impact factor: 3.436

2.  Prenatal hyperechogenic kidneys in three cases of infantile hypercalcemia associated with SLC34A1 mutations.

Authors:  Marguerite Hureaux; Arnaud Molin; Nadine Jay; Anne Hélène Saliou; Emmanuel Spaggiari; Rémi Salomon; Alexandra Benachi; Rosa Vargas-Poussou; Laurence Heidet
Journal:  Pediatr Nephrol       Date:  2018-06-29       Impact factor: 3.714

3.  From Theory to Reality: Establishing a Successful Kidney Genetics Clinic in the Outpatient Setting.

Authors:  Andrew L Lundquist; Renee C Pelletier; Courtney E Leonard; Winfred W Williams; Katrina A Armstrong; Heidi L Rehm; Eugene P Rhee
Journal:  Kidney360       Date:  2020-08-12

4.  Fluconazole in hypercalciuric patients with increased 1,25(OH)2D levels: the prospective, randomized, placebo-controlled, double-blind FLUCOLITH trial.

Authors:  Aurélia Bertholet-Thomas; Aurélie Portefaix; Sacha Flammier; Carole Dhelens; Fabien Subtil; Laurence Dubourg; Valérie Laudy; Myrtille Le Bouar; Inesse Boussaha; Marietou Ndiaye; Arnaud Molin; Sandrine Lemoine; Justine Bacchetta
Journal:  Trials       Date:  2022-06-16       Impact factor: 2.728

Review 5.  Progress in Understanding the Genetics of Calcium-Containing Nephrolithiasis.

Authors:  John A Sayer
Journal:  J Am Soc Nephrol       Date:  2016-12-08       Impact factor: 10.121

6.  CYP24A1 Mutation in a Girl Infant with Idiopathic Infantile Hypercalcemia.

Authors:  Jens Otto Broby Madsen; Sabrina Sauer; Bodo Beck; Jesper Johannesen
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-09-06

7.  Hereditary Hypercalcemia Caused by a Homozygous Pathogenic Variant in the CYP24A1 Gene: A Case Report and Review of the Literature.

Authors:  Daniele Cappellani; Alessandro Brancatella; Martin Kaufmann; Angelo Minucci; Edda Vignali; Domenico Canale; Elisa De Paolis; Ettore Capoluongo; Filomena Cetani; Glenville Jones; Claudio Marcocci
Journal:  Case Rep Endocrinol       Date:  2019-04-08

8.  Mild Idiopathic Infantile Hypercalcemia-Part 1: Biochemical and Genetic Findings.

Authors:  Nina Lenherr-Taube; Edwin J Young; Michelle Furman; Yesmino Elia; Esther Assor; David Chitayat; Tami Uster; Susan Kirwin; Katherine Robbins; Kathleen M B Vinette; Alan Daneman; Christian R Marshall; Carol Collins; Kenneth Thummel; Etienne Sochett; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

9.  The hypercalcaemia of CYP24A1 inactivation: new ways to improve diagnosis and treatment.

Authors:  Adriana S Dusso; Carlos Gomez-Alonso; Jorge B Cannata-Andia
Journal:  Clin Kidney J       Date:  2015-07-06

10.  Successful treatment of hypercalcaemia associated with a CYP24A1 mutation with fluconazole.

Authors:  Judith Sayers; Ann Marie Hynes; Shalabh Srivastava; Frances Dowen; Richard Quinton; Harish K Datta; John A Sayer
Journal:  Clin Kidney J       Date:  2015-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.